Tag Archive for USANA

USANA Reports Second Q2 Sales of $238 Million

USANA Health Sciences (NYSE: USNA) recently announced its financial results for the second fiscal quarter ending July 1, 2023.
The company achieved second quarter net sales of $238 million during this period, compared to $264 million in the second quarter of 2022. Diluted EPS was $0.89, down from $1 in the second quarter of 2022. The company’s active customers totaled 487,000, a 13% decline from the same quarter of 2022, and a 1% decline sequentially.
The Asia Pacific region led as the strongest market for the company, with $194 million in net sales and 384,000 active customers, representing an 11% and 12% decline respectively from the second quarter of 2022. Americas and Europe accounted for $44 million in net sales and 103,000 active customers.
“Our strategic focus remains squarely on increasing the number of Active Customers,”
said Jim Brown, USANA President and Chief Executive Officer.
“In addition to the emphasis on in-person meetings and events, our efforts include new market expansion, incentive opportunities for our salesforce, the ongoing pursuit of accretive acquisition opportunities, and expanding our digital commerce capabilities.
We remain optimistic that the successful execution of our strategies will position USANA for a return to long-term growth.”
USANA updated its fiscal 2023 net sales

Read more...

USANA Plans to Expand Into India

USANA Health Sciences, Inc. (NYSE: USNA) recently announced its plans to expand into India in the second half of 2023.
Expansion into India increases the Company’s global footprint to 25 markets.
“USANA’s expansion into India is our first new market in five years and provides an exciting and gratifying opportunity to introduce USANA’s world class health and wellness products to a new country, culture and demographic,”
said Jim Brown, President.
“We have spent several years of extensive research and meticulous work to prepare for this expansion into India.
We are confident that our products and business model are ideally suited for India, and we believe in our team’s ability to develop and grow this important market as we work toward our vision of creating the healthiest family on earth.
“While we are optimistic about the long-term growth opportunity that India presents, we also recognize that there will be learning opportunities as we serve an entirely new culture.
As such, we will take a deliberate and diligent approach to launching this market and executing our long-term growth strategy.”
The Company expects to officially launch operations in India near the end of the third quarter of 2023 and anticipates that this new market will contribute modestly to

Read more...

USANA Appoints Jim Brown As CEO

USANA Health Sciences, Inc. (NYSE: USNA) announced that consistent with the Company’s planned succession strategy, Kevin Guest, USANA’s Chief Executive Officer (CEO) since 2015 and Chairman of the Board since 2020, will transition to the role of Executive Chairman of the Company, effective July 1, 2023. At that time, Jim Brown, USANA’s current President, will be named CEO of the Company.
“It has been my great privilege to be part of USANA for over 30 years and to serve as CEO of this remarkable company for the last 8 years. I express my sincere appreciation for, and confidence in, USANA’s extraordinary management team, employees and Associates for their relentless work in advancing USANA’s position as one of the foremost leaders in health and wellness.
I look forward to my new role as Executive Chairman of the Company, where I will continue to be deeply involved in setting and advancing the Company’s strategy and mission.”
Gilbert Fuller, lead independent director of USANA’s Board of Directors said
“During his tenure with USANA, Kevin’s leadership, contributions, and passion for USANA’s mission and values have been immeasurable. As we move through this planned leadership transition, we look forward to Kevin’s ongoing involvement with the Company as Executive

Read more...

USANA Sales 2022 Down 16% To $999 Million

USANA Health Sciences, Inc. announced financial results for its fiscal fourth quarter and full year ended December 31, 2022.
Key Financial & Operating Results

Fourth quarter net sales were $228 million versus $267 million during the prior-year period.
Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021.
Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021.
Fiscal year 2022 diluted EPS totaled $3.59 versus $5.73 during fiscal year 2021.
Fiscal year 2022 operating cash flow totaled $104 million.
Company reiterates fiscal year 2023 net sales and diluted EPS outlook of $850 million to $950 million and $2.35 to $3.30, respectively.

“Our fourth quarter and full year results were largely in line with our preliminary results announced on January 5, 2023,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“During the fourth quarter, total Active Customer counts stabilized in several key markets and increased 3% sequentially. In addition, sales and customer activity in mainland China increased during the final two weeks of the year following the Chinese government’s unanticipated shift in COVID policy. This increase in sales and customer activity was due largely to increased demand for several of our health products in China.”
“While 2022

Read more...

USANA Acquires Network Marketing Company Oola

USANA Health Sciences, Inc. (NYSE: USNA) today announced the acquisition of two companies—Rise Bar and Oola.

“The acquisition of these emerging companies is part of USANA’s long-term growth strategy”

These emerging companies share USANA’s health and wellness focus while offering distinct channels or products. Rise Bar manufactures and sells high-quality protein bars that are formulated to help customers achieve their health goals through clean and simple ingredients.
Oola is an emerging direct selling company that offers a personal development framework that helps individuals create a life of balance, growth, and purpose.
Although Rise Bar and Oola will continue to operate and grow independently, USANA plans to leverage the knowledge, experience, and technology of these companies to advance USANA’s core business. Likewise, USANA will utilize its assets and resources to facilitate growth for Rise Bar and Oola.
“The acquisition of these emerging companies is part of USANA’s long-term growth strategy,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“We are committed to improving the health and wellness of individuals around the world. While USANA is a leader in many aspects, we recognize that we can accelerate this effort and reach more individuals through strategic acquisitions that align with our corporate values and mission.
“Both Rise

Read more...

USANA Q3 Revenue Down 15 % To $233 Million

USANA Health Sciences, Inc. announced financial results for its fiscal third quarter ended October 1, 2022. Key Financial & Operating Results:
Third quarter net sales were $233 million as compared with $274 million during the third quarter of the prior year. Third quarter diluted EPS totaled $0.78 versus $1.36 during the third quarter of 2021. Company revises fiscal 2022 net sales and diluted EPS outlook to $955 million to $975 million and $3.15 to $3.40, respectively.
Q3 2022 Financial Performance – Consolidated Results
Net Sales $233 million

-15% vs. prior-year quarter
-9% constant currency vs. prior-year quarter
-$15 million YOY FX impact, or -6%
-9% sequentially in constant currency
Diluted EPS $0.78 -43% vs. prior-year quarter -22% sequentially
Diluted shares of 19.3 million, -4% year-over-year
Active Customers 474,000 -18% vs. prior-year quarter -15% sequentially

“The challenging operating environment in Asia Pacific and the strengthening U.S. dollar negatively affected our operating results in the third quarter,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“COVID-related disruptions and challenging economic conditions resulting from those disruptions negatively impacted our results in several key Asia Pacific markets where city-wide lockdowns and other COVID restrictions persisted. This difficult operating environment has impacted our entire industry.”
Guest continued,
“While we remain committed to our long-term business strategy,

Read more...

USANA Q2 Revenue Down 21% To $264 Million

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 2, 2022.

Second quarter net sales were $264 million as compared with $337 million during the second quarter of the prior year.
Second quarter diluted EPS totaled $1.00 versus $1.87 during the second quarter of 2021.
Company reiterates fiscal 2022 net sales and diluted EPS outlook of $1.015 billion to $1.065 billion and $3.85 to $4.45, respectively.

“As indicated in our preliminary results release on July 6th, we continue to experience COVID-related disruptions in several key markets, including mainland China. This caused participation in sales programs, Active Customer counts, and financial performance to come in lower than anticipated,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“Although many of these disruptions were outside of our control, and while we faced a tough year-over year comparable due to the timing of a successful sales program in 2021, our second quarter results were not up to our standards.
Nevertheless, we remain committed to our business strategy which we believe will deliver sustained, long-term growth in customer counts, net sales, and EPS.
Important elements of this strategy include

enhancing digital experience for our customers to improve the overall online shopping experience;
improving

Read more...

USANA Q2 Preliminary Sales Down 21% To $265 Million

USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary results for the second quarter ended July 2, 2022, and provided an updated outlook for fiscal year 2022.
The Company anticipates that second quarter 2022 net sales will be approximately $265 million, which compares with $337 million in the prior-year period. Earnings per share for the quarter are expected to be approximately $1.05, which compares with $1.87 during the second quarter of 2021.
“Our sales performance during the second quarter was below expectations, as COVID-related lockdowns, restrictions, and other disruptions continued in mainland China and other markets,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“These challenges were particularly disruptive to the regional sales program we offered in several key markets during the quarter, and ultimately caused participation in the program, sales results and active customer counts to come in lower than anticipated.
Importantly, this program was designed to be a catalyst for sales and customer growth not only during the quarter, but also in the second half of the year. As a result of this and the continued uncertainty surrounding the operating environment going forward, we anticipate softer sales and customer counts in the second half of the year.”
“We continue to

Read more...

USANA Q3 Revenue Up 13.4% To $296.8 Million

Third quarter net sales of$296.8 million, an increase of 13.4% year-over-year

Third quarter diluted earnings per share increased 27.8% year-over-year to$1.24

Total Active Customers increased 9.2% year-over-year to 615,000

Board increases share repurchase authorization

SALT LAKE CITY–(BUSINESS WIRE)– USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 29, 2018.
Financial Performance
For the third quarter of 2018, net sales were $296.8 million, compared with $261.8 million in the prior-year period, a 13.4% increase year-over-year. Unfavorable currency exchange rates negatively impacted net sales by $6.2 million for the quarter as compared to the prior year. The Company’s skin and personal care product category contributed approximately $9.5 million in incremental sales for the quarter. The Company’s total number of active Customers increased 9.2% year-over-year to 615,000.
Net earnings for the third quarter increased 30.6% to $31.0 million, compared with net earnings of $23.8 million reported in the prior-year period. Earnings per diluted share increased to $1.24, an increase of 27.8% on a year-over-year basis. The increase in net earnings was due primarily to higher net sales and lower relative operating expenses compared to the prior year period. Weighted average diluted shares outstanding were 25.0 million for the third quarter of 2018, compared with diluted shares of 24.6 million in the prior-year period.
“We

Read more...

USANA On List Of Most Trustworthy Public Companies In The USA

Trust is a vital factor for consumers and investors when looking into a company — and for USANA, trust is everything.
To this end, USANA has been selected by TGF Analytics as one of “America’s Most Trustworthy Public Companies.”
USANA was ranked fourth among “small/mid cap” companies with an A+ rating — something only five percent of companies researched achieved.
The rankings were based on dozens of factors in five key areas: Financial Governance, Environmental, Social & Corporate Governance (ESG), Quality of Earnings, Relative Risk, and Market-Implied Governance.
“USANA is a company that prides itself on being trustworthy, whether it’s from the overall quality of our products to the information we provide to our investors,”
said Kevin Guest, USANA’s chief executive officer.
“We are delighted to be recognized for our efforts in building trust with the public, and would also like to congratulate the other companies on this prestigious list.”
“Trust is a keystone to all good relationships — those between investor and the company in which the investment is placed, between creditors and the recipients of credit, between customers and businesses they patronize, employees and the workplace, suppliers and with whom they contract, and more,” said David R. Koenig, founding principal of TGF Analytics. “Trust

Read more...